ERBB2 and breast neoplasm: Compliance with adjuvant chemotherapy recommendations was generally low, which can be partly explained by the use of neoadjuvant chemotherapy, which has been largely implemented in recent years, particularly in breast tumors with aggressive phenotypes (triple-negative or HER2-positive).